| Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled … F Ader, M Bouscambert-Duchamp, M Hites, N Peiffer-Smadja, J Poissy, ... The Lancet infectious diseases 22 (2), 209-221, 2022 | 341 | 2022 |
| Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis JP Lanoix, AJ Lenaerts, EL Nuermberger Disease models & mechanisms 8 (6), 603-610, 2015 | 110 | 2015 |
| An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 F Ader, N Peiffer-Smadja, J Poissy, M Bouscambert-Duchamp, D Belhadi, ... Clinical Microbiology and Infection 27 (12), 1826-1837, 2021 | 104 | 2021 |
| Characteristics and outcomes of COVID‐19 in hospitalized patients with and without diabetes A Al‐Salameh, JP Lanoix, Y Bennis, C Andrejak, E Brochot, G Deschasse, ... Diabetes/metabolism research and reviews 37 (3), e3388, 2021 | 104 | 2021 |
| Dynamic profile for the detection of anti-SARS-CoV-2 antibodies using four immunochromatographic assays B Demey, N Daher, C François, JP Lanoix, G Duverlie, S Castelain, ... Journal of Infection 81 (2), e6-e10, 2020 | 89 | 2020 |
| Host-mediated bioactivation of pyrazinamide: implications for efficacy, resistance, and therapeutic alternatives LE Via, R Savic, DM Weiner, MD Zimmerman, B Prideaux, SM Irwin, ... ACS infectious diseases 1 (5), 203-214, 2015 | 82 | 2015 |
| Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus JP Lanoix, AM Bourgeois, J Schmidt, J Desblache, V Salle, A Smail, ... Lupus 20 (2), 125-130, 2011 | 70 | 2011 |
| Selective inactivity of pyrazinamide against tuberculosis in C3HeB/FeJ mice is best explained by neutral pH of caseum JP Lanoix, T Ioerger, A Ormond, F Kaya, J Sacchettini, V Dartois, ... Antimicrobial agents and chemotherapy 60 (2), 735-743, 2016 | 69 | 2016 |
| Mutations in fbiD (Rv2983) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis D Rifat, SY Li, T Ioerger, K Shah, JP Lanoix, J Lee, G Bashiri, J Sacchettini, ... Antimicrobial agents and chemotherapy 65 (1), 10.1128/aac. 01948-20, 2020 | 64 | 2020 |
| Bacterial infection profiles in lung cancer patients with febrile neutropenia JP Lanoix, E Pluquet, FX Lescure, H Bentayeb, E Lecuyer, M Boutemy, ... BMC Infectious Diseases 11, 1-7, 2011 | 63 | 2011 |
| Trajectories of hospitalization in COVID-19 patients: an observational study in France PY Boëlle, T Delory, X Maynadier, C Janssen, R Piarroux, M Pichenot, ... Journal of clinical medicine 9 (10), 3148, 2020 | 61 | 2020 |
| Association between renin–angiotensin system inhibitors and COVID-19 complications S Liabeuf, J Moragny, Y Bennis, B Batteux, E Brochot, JL Schmit, ... European Heart Journal-Cardiovascular Pharmacotherapy 7 (5), 426-434, 2021 | 52 | 2021 |
| Tuberculosis in the intensive care unit: a descriptive analysis in a low-burden country JP Lanoix, S Gaudry, R Flicoteaux, R Ruimy, M Wolff The International journal of tuberculosis and lung disease 18 (5), 581-587, 2014 | 47 | 2014 |
| Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial V Dubée, PM Roy, B Vielle, E Parot-Schinkel, O Blanchet, A Darsonval, ... Clinical Microbiology and Infection 27 (8), 1124-1130, 2021 | 45 | 2021 |
| The association between body mass index class and coronavirus disease 2019 outcomes A Al-Salameh, JP Lanoix, Y Bennis, C Andrejak, E Brochot, G Deschasse, ... International Journal of Obesity 45 (3), 700-705, 2021 | 44 | 2021 |
| In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the … P Gopal, R Tasneen, M Yee, JP Lanoix, J Sarathy, G Rasic, L Li, V Dartois, ... ACS infectious diseases 3 (7), 492-501, 2017 | 43 | 2017 |
| Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosis JP Lanoix, F Betoudji, E Nuermberger Antimicrobial agents and chemotherapy 58 (4), 2316-2321, 2014 | 43 | 2014 |
| Use of dipeptidyl peptidase‐4 inhibitors and prognosis of COVID‐19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study R Roussel, P Darmon, M Pichelin, T Goronflot, Y Abouleka, L Ait Bachir, ... Diabetes, Obesity and Metabolism 23 (5), 1162-1172, 2021 | 39 | 2021 |
| Shortening tuberculosis treatment with fluoroquinolones: lost in translation? JP Lanoix, RE Chaisson, EL Nuermberger Clinical Infectious Diseases 62 (4), 484-490, 2016 | 38 | 2016 |
| Sterilizing activity of pyrazinamide in combination with first-line drugs in a C3HeB/FeJ mouse model of tuberculosis JP Lanoix, F Betoudji, E Nuermberger Antimicrobial agents and chemotherapy 60 (2), 1091-1096, 2016 | 32 | 2016 |
